You are here: Industry Insights > Charles River

News List

Charles River, Valo Enter AI-enabled Drug Discovery Pact contractpharma
January 19, 2022
Multiyear partnership will leverage Valo’s Opal Computational Platform to accelerate drug discovery and development.
Pharmaceutical QC market to value $9,700mn by 2027 europeanpharmaceuticalreview
July 02, 2021
Market research shows increasing pharmaceutical R&D investment and advances in quality control (QC) technologies will drive pharmaceutical QC market growth.
Charles River to Acquire Vigene Biosciences contractpharma
May 18, 2021
Charles River Laboratories International Inc. has signed a definitive agreement to acquire Vigene Biosciences Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene ...
Charles River Acquires Retrogenix contractpharma
April 06, 2021
Charles River Laboratories has acquired early-stage contract research organization (CRO) Retrogenix, a provider of specialized bioanalytical services utilizing its proprietary cell microarray technology, for $48 million.
Charles River Acquires CDMO Cognate BioServices contractpharma
February 18, 2021
Charles River Laboratories has signed an agreement to acquire Cognate BioServices, a cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million.
Charles River Partners with JADE contractpharma
January 15, 2021
Charles River Laboratories International Inc. has entered into a strategic partnership with JADE Biomedical (JADE), a provider of end-to-end quality management services for the biopharmaceutical industry.
PathoQuest, Charles River Expand Strategic Pact contractpharma
November 13, 2020
Establishes a biologics genomic testing laboratory in Wayne, PA to expand next-generation sequencing capabilities.
Takeda partners Charles River to develop preclinical candidates pharmaceutical-technology
January 16, 2020
Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas. Under the multi-year drug discovery collaboration, the two companies will work on multiple integrated programmes for o
Charles River Laboratories to acquire HemaCare for $380m pharmaceutical-technology
December 18, 2019
Charles River Laboratories International has signed a definitive agreement to acquire cellular products developer HemaCare for a cash consideration of approximately $380m.
Charles River & CHDI Extend Partnership contractpharma
April 15, 2019
Five-year extension of their ongoing collaboration that started in 2005 for the drug discovery and development for Huntington’s disease...

Previous page 1 2 Next page